Viela Bio

Products & Pipeline

Pipeline

Targeting Autoimmune and Inflammatory Diseases Via Critical Biological Pathways

Autoimmune diseases are the result of an individual’s immune system attacking its own healthy cells and tissue. These diseases often involve autoreactive T cells and B cells, which communicate through shared biological pathways. In a healthy individual, these T cells and B cells are eliminated or suppressed. If these processes fail, however, autoantibodies—a product of autoreactive B cells—may form resulting in recurring bouts of disease flares followed by periods of remission.

At Viela Bio, we are developing a pipeline of novel therapies that address a wide range of autoimmune and severe inflammatory diseases. Our approach focuses on shared critical biological pathways to target the underlying cause of autoimmune disease. We recently announced that the U.S. FDA approved UPLIZNA® (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive. In parallel to initiating the commercialization of UPLIZNA®, we continue to expand on the opportunity by advancing multiple clinical trials with inebilizumab in various indications including myasthenia gravis, IgG4-related disease, and kidney transplant rejection. Our pipeline also includes novel candidates, VIB4920 and VIB7734, which we are pursuing for the treatment of a variety of serious and debilitating autoimmune diseases.

Pipeline Chart

Molecule
(mechanism)
Indication Development Stage Status/Potential
Future Milestone
Global
Rights
PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED
Inebilizumab-
cdon
(Anti-CD19 mAb)
Molecule
(mechanism)
PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED
Inebilizumab-
cdon
(Anti-CD19 mAb)

Neuromyelitis Optica
Spectrum Disorder

uplizna logo
Commercial (U.S.)
June 2020

Viela Bio
Status/Potential
Future Milestone

Commercial (U.S.)
June 2020

Global
RightsViela Bio

Myasthenia Gravis

Phase 3 Trial

Viela Bio
Status/Potential
Future Milestone

Phase 3 Trial

Global
RightsViela Bio

IgG4-Related
Disease

Phase 3 Trial

Viela Bio
Status/Potential
Future Milestone

Phase 3 Trial

Global
RightsViela Bio

Kidney Transplant
Desensitization

Phase 2 Trial

Viela Bio
Status/Potential
Future Milestone

Phase 2 Trial

Global
RightsViela Bio
 
VIB4920
(Anti-CD40L-Tn3
Fusion Protein)
Molecule
(mechanism)
PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED
VIB4920
(Anti-CD40L-Tn3
Fusion Protein)

Sjögren's Syndrome

Phase 2b Trial

Viela Bio
Status/Potential
Future Milestone

Phase 2b Trial

Global
RightsViela Bio

Kidney Transplant
Rejection

Phase 2 Trial

Viela Bio
Status/Potential
Future Milestone

Phase 2 Trial

Global
RightsViela Bio

Rheumatoid Arthritis

Phase 2 Trial

Viela Bio
Status/Potential
Future Milestone

Phase 2 Trial

Global
RightsViela Bio
 
VIB7734
(Anti-ILT7 mAb)
Molecule
(mechanism)
PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED
VIB7734
(Anti-ILT7 mAb)

Systemic Lupus
Erythematosus2

Phase 2 Trial (planned)

Viela Bio
Status/Potential
Future Milestone

Phase 2 Trial (planned)

Global
RightsViela Bio

Cutaneous Lupus
Erythematosus2

Phase 1b Trial

Viela Bio
Status/Potential
Future Milestone

Phase 1b Trial

Global
RightsViela Bio

COVID-19-Related Acute Lung Injury

Phase 1 Trial

Viela Bio
Status/Potential
Future Milestone

Phase 1 Trial

Global
RightsViela Bio
 

1 We have entered into collaboration agreements with Hansoh Pharmaceutical Group and Mitsubishi Tanabe Pharma to develop and market inebilizumab-cdon in China, Hong Kong and Macau and Japan and other Asia regions, respectively.​

2 This indication is one of six potential indications being studied in our ongoing Phase 1b multiple ascending dose trial, along with systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, polymyositis and dermatomyositis.